DOCSLIB.ORG

Aldrich FT-IR Collection Edition I Library

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Aldrich FT-IR Collection Edition I Library Aldrich FT-IR Collection Edition I Library Library Listing – 10,505 spectra This library is the original FT-IR spectral collection from Aldrich. It includes a wide variety of pure chemical compounds found in the Aldrich Handbook of Fine Chemicals. The Aldrich Collection of FT-IR Spectra Edition I library contains spectra of 10,505 pure compounds and is a subset of the Aldrich Collection of FT-IR Spectra Edition II library. All spectra were acquired by Sigma-Aldrich Co. and were processed by Thermo Fisher Scientific. Eight smaller Aldrich Material Specific Sub-Libraries are also available. Aldrich FT-IR Collection Edition I Index Compound Name Index Compound Name 3515 ((1R)-(ENDO,ANTI))-(+)-3- 928 (+)-LIMONENE OXIDE, 97%, BROMOCAMPHOR-8- SULFONIC MIXTURE OF CIS AND TRANS ACID, AMMONIUM SALT 209 (+)-LONGIFOLENE, 98+% 1708 ((1R)-ENDO)-(+)-3- 2283 (+)-MURAMIC ACID HYDRATE, BROMOCAMPHOR, 98% 98% 3516 ((1S)-(ENDO,ANTI))-(-)-3- 2966 (+)-N,N'- BROMOCAMPHOR-8- SULFONIC DIALLYLTARTARDIAMIDE, 99+% ACID, AMMONIUM SALT 2976 (+)-N-ACETYLMURAMIC ACID, 644 ((1S)-ENDO)-(-)-BORNEOL, 99% 97% 9587 (+)-11ALPHA-HYDROXY-17ALPHA- 965 (+)-NOE-LACTOL DIMER, 99+% METHYLTESTOSTERONE 5127 (+)-P-BROMOTETRAMISOLE 9590 (+)-11ALPHA- OXALATE, 99% HYDROXYPROGESTERONE, 95% 661 (+)-P-MENTH-1-EN-9-OL, 97%, 9588 (+)-17-METHYLTESTOSTERONE, MIXTURE OF ISOMERS 99% 730 (+)-PERSEITOL 8681 (+)-2'-DEOXYURIDINE, 99+% 7913 (+)-PILOCARPINE 7591 (+)-2,3-O-ISOPROPYLIDENE-2,3- HYDROCHLORIDE, 99% DIHYDROXY- 1,4- 5844 (+)-RUTIN HYDRATE, 95% BIS(DIPHENYLPHOSPHINO)BUT 9571 (+)-STIGMASTANOL 976 (+)-2,3-O-ISOPROPYLIDENE-L- 663 (+)-TERPINEN-4-OL, 96% THREITOL, 99% 9574 (+)-VITAMIN D3, CRYSTALLINE, 1754 (+)-3- 99+% (TRIFLUOROACETYL)CAMPHOR, 1375 (+/-)-1,2-DIMETHYLPYRROLIDINE, 98% 97% 9584 (+)-4-CHOLESTEN-3-ONE, 98% 5167 (+/-)-1-(5-CHLORO-2- 8683 (+)-5-BROMO-2'-DEOXYURIDINE, (METHYLAMINO)PHENYL)- 1,2,3,4- 97% TETRAHYDROISOQUINOL 8685 (+)-5-FLUORODEOXYURIDINE, 3512 (+/-)-10-CAMPHORSULFONIC ACID 98+% MONOHYDRATE, 98% 8684 (+)-5-IODO-2'-DEOXYURIDINE, 98% 3513 (+/-)-10-CAMPHORSULFONIC ACID, 9618 (+)-5ALPHA-ANDROSTAN-17BETA- SODIUM SALT, 97% OL-3-ONE BENZOATE, 98% 1673 (+/-)-2,4- 3105 (+)-6-AMINOPENICILLANIC ACID, DIMETHYLCYCLOPENTANONE, 96% 99%, MIXTURE OF CIS AND TRANS 9594 (+)-ANDROSTA-1,4-DIENE-3,17- 2282 (+/-)-4-AMINO-3- DIONE, 98% HYDROXYBUTYRIC ACID, 98% 778 (+)-ARABINOGALACTAN 6080 (+/-)-4-CHLORO-ALPHA- 6987 (+)-BIOTIN 4-NITROPHENYL METHYLPHENYLACETIC ACID, ESTER, 99% 98% 3175 (+)-BIOTIN, 99% 2835 (+/-)-CAMPHORIC ANHYDRIDE 207 (+)-CAMPHENE, TECH., 80% 5081 (+/-)-EPINEPHRINE, 99% 4586 (+)-CATECHIN HYDRATE, 98% 646 (+/-)-ISOPINOCAMPHEOL, 98% 8867 (+)-CINCHONINE, 85% 2451 (+/-)-MENTHYL ACETATE, 9631 (+)-CYMARIN MIXTURE OF CIS AND TRANS 8766 (+)-CYTIDINE-5'- 675 (+/-)-PATCHENOL, TECH., 90% MONOPHOSPHORIC ACID 2764 (+/-)-TEREBIC ACID, 98+% HYDRATE, 99% 2017 (+/-)-THREO-9,10- 9578 (+)-DEHYDROISOANDROSTERONE, DIHYDROXYSTEARIC ACID, 97% 97% 2095 (+/-)-TRANS-1,2- 9626 (+)-DIGITOXIGENIN, 98% CYCLOBUTANEDICARBOXYLIC 9632 (+)-DIGOXIN, 97% ACID 1732 (+)-DIHYDROCARVONE, 98%, 632 (+/-)-TRANS-1,2- MIXTURE OF ISOMERS CYCLOHEPTANEDIOL, 98% 9567 (+)-DIHYDROCHOLESTEROL, 95% 5168 (-)-1-(5-CHLORO-2- 9659 (+)-EMETINE DIHYDROCHLORIDE METHYLAMINO)PHENYL)-1,2,3,4- HYDRATE, 97% TETRAHYROISOQUINOLINE 2767 (+)-GIBBERELLIC ACID, 90+% 7555 (-)-1-CHLORO-3-TOSYLAMIDO-7- 5172 (+)-GLAUCINE, 97% AMINO-2- HEPTANONE 6723 (+)-GRISEOFULVIN HYDROCHLORIDE, 98% 668 (+)-LIMONEN-10-OL, 95% 8288 (-)-2'-DEOXYINOSINE, 99% (c) 2007 Thermo Fisher Scientific Inc. All rights reserved. Page 1 of 148 Aldrich FT-IR Collection Edition I Index Compound Name Index Compound Name 7592 (-)-2,3-O-ISOPROPYLIDENE-2,3- 929 (-)-LIMONENE OXIDE, 97%, DIHYDROXY- 1,4- MIXTURE OF CIS AND TRANS BIS(DIPHENYLPHOSPHINO)BUT 5658 (-)-LOBELINE HYDROCHLORIDE, 975 (-)-2,3-O-ISOPROPYLIDENE-D- 98% THREITOL, 99% 1686 (-)-MENTHONE, 90% 8284 (-)-2-AMINO-6-CHLOROPURINE 2037 (-)-MENTHOXYACETIC ACID, 98% RIBOSIDE, 96% 415 (-)-MENTHYL CHLORIDE, 99+% 8286 (-)-2-AMINO-6-MERCAPTOPURINE 2898 (-)-MENTHYL CHLOROFORMATE RIBOSIDE HYDRATE, 98% 2977 (-)-N-ACETYLNEURAMINIC ACID, 2011 (-)-2-HYDROXYISOCAPROIC ACID, SYNTHETIC, CRYSTALLINE 98% 5188 (-)-N-DODECYL-N- 6475 (-)-3-(3,4-DIHYDROXYPHENYL)-2- METHYLEPHEDRINIUM METHYL-L- ALANINE BROMIDE,99% SESQUIHYDRATE, 99% 9630 (-)-OUABAIN OCTAHYDRATE, 98% 9566 (-)-5-ANDROSTENE- 5128 (-)-P-BROMOTETRAMISOLE 3BETA,17BETA-DIOL HYDRATE OXALATE, 99% 8053 (-)-5-BROMO-4-CHLORO-3- 8985 (-)-RIBOFLAVIN, 98% INDOLYL BETA-D- GLUCOSIDE, 3543 (-)-SINIGRIN MONOHYDRATE, 98% 98% 1488 (-)-SPARTEINE SULFATE 8677 (-)-5-BROMOURIDINE, 99+% PENTAHYDRATE, 99% 8289 (-)-6-(METHYLAMINO)PURINE 9641 (-)-STRYCHNINE, 98% RIBOSIDE, 97% 3809 (1,2-DIBROMOETHYL)BENZENE, 8798 (-)-6-AZAURIDINE 2',3',5'- 99% TRIACETATE 7611 (1,3-DIOXOLAN-2- 9572 (-)-7-DEHYDROCHOLESTEROL, YLMETHYL)TRIPHENYLPHOSPHO 98% NIUM BROMIDE, 98% 8312 (-)-ADENOSINE 3',5'-CYCLIC 3806 (1-BROMOETHYL)BENZENE, 97% MONOPHOSPHATE, 98% 3350 (1-ETHOXYETHYLIDENE)- 8308 (-)-ADENOSINE 3'- MALONONITRILE, 98% MONOPHOSPHATE HYDRATE, 99% 6142 (1-NAPHTHOXY)ACETIC ACID, 98% 8307 (-)-ADENOSINE 5'- 196 (1R)-(+)-ALPHA-PINENE, 98% (91+% MONOPHOSPHATE EE/GLC) MONOHYDRATE, 99% 1705 (1R)-(+)-CAMPHOR, 98% 8292 (-)-ADENOSINE, 99+% 3514 (1R)-(-)-10-CAMPHORSULFONIC 2452 (-)-BORNYL ACETATE, 97% ACID, AMMONIUM SALT 208 (-)-CAMPHENE, 95% 1703 (1R)-(-)-FENCHONE, 98+% 669 (-)-CARVEOL, 97%, MIXTURE OF 1848 (1R)-(-)-MYRTENAL, 98% ISOMERS 676 (1R)-(-)-MYRTENOL, 95% 2515 (-)-CARVYL ACETATE, 98+%, 677 (1R)-(-)-NOPOL, 98% MIXTURE OF ISOMERS 643 (1R)-ENDO-(+)-FENCHYL 2517 (-)-CARVYL PROPIONATE, 98%, ALCOHOL, 96% MIXTURE OF ISOMERS 4992 (1R,2R)-(-)- 1236 (-)-CIS-MYRTANYLAMINE, 98% NORPSEUDOEPHEDRINE 6664 (-)-COREY LACTONE, 4- HYDROCHLORIDE, 98% PHENYLBENZOATE ALCOHOL, 647 (1R,2R,3R,5S)-(-)- 99% ISOPINOCAMPHEOL, 98% 8741 (-)-CYCLOCYTIDINE 5012 (1R,2S)-(+)-2-AMINO-1-PHENYL-1,3- HYDROCHLORIDE, 98% PROPANEDIOL, 99% 2514 (-)-DIHYDROCARVYL ACETATE, 5009 (1R,2S)-(-)-EPHEDRINE NITRATE, 95+%, MIXTURE OF ISOMERS 99% 9642 (-)-EBURNAMONINE, 98+% 5008 (1R,2S)-(-)-EPHEDRINE, 99% 4587 (-)-EPICATECHIN, 97% 4993 (1R,2S)-(-)-N-METHYLEPHEDRINE, 2761 (-)-ERYTHROMYCIN HYDRATE, 99% 96% 617 (1R,2S,5R)-(-)-MENTHOL, 99% 3090 (-)-GLUTATHIONE, OXIDIZED, 90% 2032 (1R,3R,4R,5R)-(-)-QUINIC ACID, 98% 9623 (-)-HECOGENIN ACETATE, TECH., 2098 (1R,3S)-(+)-CAMPHORIC ACID, 99% 90% 3511 (1S)-(+)-10-CAMPHORSULFONIC 8263 (-)-INOSINE, 99% ACID, 99% 8291 (-)-KINETIN RIBOSIDE 3540 (1S)-(+)-10-CAMPHORSULFONYL CHLORIDE, 97% (c) 2007 Thermo Fisher Scientific Inc. All rights reserved. Page 2 of 148 Aldrich FT-IR Collection Edition I Index Compound Name Index Compound Name 197 (1S)-(-)-ALPHA-PINENE, 98% (81+% 6143 (2-NAPHTHOXY)ACETIC ACID, 98% EE/GLC) 7041 (2-NAPHTHOXY)ACETIC ACID, N- 206 (1S)-(-)-BETA-PINENE, 99% HYDROXYSUCCIN-IMIDE ESTER, 2789 (1S)-(-)-CAMPHANIC ACID 98% MONOHYDRATE, 99% 3679 (2.2)PARACYCLOPHANE, 97% 2924 (1S)-(-)-CAMPHANIC CHLORIDE, 512 (2R,3R)-(-)-2,3-BUTANEDIOL, 97% 98% 519 (2R,4R)-(-)-PENTANEDIOL, 99% 1706 (1S)-(-)-CAMPHOR, 95% 1725 (2S,3S)-(+)-2-ALLYL-3-HYDROXY-2- 4131 (1S)-(-)-NOPOL BENZYL ETHER, METHYL CYCLOPENTANONE, 95% 95% 7590 (2S,3S)-(-)- 1740 (1S)-(-)-VERBENONE, 94% (50+% BIS(DIPHENYLPHOSPHINO)BUTAN EE/GLC) E 620 (1S, 2S, 5R)-(+)-NEOMENTHOL, 97% 6116 (3,4-DIMETHOXYPHENYL)ACETIC 5010 (1S,2R)-(+)-EPHEDRINE ACID, 98% HYDROCHLORIDE, 99% 5482 (3,4- 5007 (1S,2R)-(+)-EPHEDRINE, 99%, DIMETHOXYPHENYL)ACETONE, ANHYDROUS 97% 4991 (1S,2R)-(+)-NOREPHEDRINE 7181 (3,4- HYDROCHLORIDE, 99% DIMETHOXYPHENYL)ACETONITRI 619 (1S,2R,5R)-(+)-ISOMENTHOL, 99% LE, 98% 618 (1S,2R,5S)-(+)-MENTHOL, 99% 6787 (3,4-DIMETHOXYPHENYL)ACETYL 5011 (1S,2S)-(+)-2-AMINO-1-PHENYL-1,3- CHLORIDE, 98% PROPANEDIOL, 98% 7607 (3-BROMOPROPYL)- 648 (1S,2S,3S,5R)-(+)- TRIPHENYLPHOSPHONIUM ISOPINOCAMPHEOL, 98% BROMIDE, 98% 3814 (2,2-DICHLOROCYCLOPROPYL)- 2264 (3- BENZENE, 97% CARBOXYPROPYL)TRIMETHYLA 7199 (2,4,7-TRINITRO-9- MMONIUM CHLORIDE, 97% FLUORENYLIDENE)- 9781 (3- MALONONITRILE, 98% CHLOROPROPYL)TRIMETHOXYSIL 6122 (2,5-DIMETHOXYPHENYL)ACETIC ANE, 97% ACID, 99% 9796 (3- 7612 (2-(1,3-DIOXAN-2- MERCAPTOPROPYL)TRIMETHOXY YL)ETHYL)TRIPHENYLPHOSPHON SILANE, 95% IUM BROMIDE, 98% 7160 (3- 7608 (2- METHOXYPHENYL)ACETONITRIL (DIMETHYLAMINO)ETHYL)TRIPHE E, 99% NYLPHOSPHONIUM BROMIDE, 7616 (4- 97% CARBOXYBUTYL)TRIPHENYLPHO 4936 (2-AMINOPHENYL)-HYDRAZINE SPHONIUM BROMIDE, 98% DIHYDROCHLORIDE 5477 (4-FLUOROPHENYL)ACETONE, 3808 (2-BROMOETHYL)BENZENE, 98% 98% 1541 (2- 7170 (4-METHOXYPHENYL)- BROMOETHYL)TRIMETHYLAMMO ACETONITRILE, 97% NIUM BROMIDE, 98% 8560 (4-PYRIDYLTHIO)ACETIC ACID, 3807 (2-CHLOROETHYL)BENZENE, 99% 98% 1540 (2- 5146 (4S,5S)-(+)-5-AMINO-2,2- CHLOROETHYL)TRIMETHYLAMM DIMETHYL-4-PHENYL-1,3- ONIUM CHLORIDE, 98% DIOXANE, 98% 5476 (2-FLUOROPHENYL)ACETONE, 5123 (4S,5S)-(-)-2-ETHYL-5-PHENYL-2- 99% OXAZOLINE-4-METHANOL 7614 (2- 5122 (4S,5S)-(-)-2-METHYL-5-PHENYL-2- HYDROXYBENZYL)TRIPHENYLPH OXAZOLINE-4-METHANOL, 98% OSPHONIUM BROMIDE, 98% 5124 (4S,5S)-(-)-4-METHOXYMETHYL-2- 7609 (2- METHYL-5- PHENYL-2- HYDROXYETHYL)TRIPHENYLPHO OXAZOLINE, 98% SPHONIUM CHLORIDE, 98% 9695 (ACETIC ANHYDRIDE)-D6, 99+ 7151 (2- ATOM % D METHOXYPHENYL)ACETONITRIL E, 98% (c) 2007 Thermo Fisher Scientific Inc. All rights reserved. Page 3 of 148 Aldrich FT-IR Collection Edition I Index Compound Name Index Compound Name 6065 (ALPHA,ALPHA,ALPHA- 9724 (METHYL-D3)- TRIFLUORO-M-TOLYL)ACETIC TRIPHENYLPHOSPHONIUM ACID, 97% BROMIDE, 99 ATOM % D 6048 (ALPHA,ALPHA,ALPHA- 1280 (METHYLAMINO)ACETALDEHYDE TRIFLUORO-O-TOLYL)ACETIC DIMETHYL ACETAL, 97% ACID, 98% 3364 (METHYLAMINO)ACETONITRILE 6075 (ALPHA,ALPHA,ALPHA- HYDROCHLORIDE, 98% TRIFLUORO-P-TOLYL)-
Load more

Recommended publications
  • Pseudo-Cholinesterase in Rat Erythrocytes Basis of Its Substrate Ratio, It Is Possible That It May Be a Butyro-Cholinesterase
    No. 4535 September 29, 1956 NATURE 697 Pseudo-cholinesterase in Rat Erythrocytes basis of its substrate ratio, it is possible that it may be a butyro-cholinesterase. .ALTHOUGH there are many references in the literature to the existence of different types of cholin­ D.R. DAVIES esterase in mammalian sera1, it is generally believed J. P. RUTLAND 2 that human red cells contain only one type • Further­ more, we can find no evidence in the literature for Chemical Defence Experimental Establishment the existence of a pseudo-cholinesterase in any (Ministry of Supply), mammalian erythrocytes, although many workers Porton, Salisbury. have stated that benzoylcholine is hydrolysed by May 3. red cells. Since, however, the rate of hydrolysis is 1 Mundell, D. B., Nature, 153, 557 (1944). Ellis, S., Sanders, S., and slow, this breakdown of a substrate formerly presumed Bodansky, 0., J. Pharmacol., 91, 225 (1947). Levine M G and Suran, A. A., Enzymologia, 15, 17 (1951). ' · ., to be specific for pseudo-cholinesterase has been 'Mendell, B., Mundell, D. B., and Rudney, H., Biochem. J. 37 473 attributed to true cholinesterase. Indeed, Adams3 (1943). ' ' has shown that purified true cholinesterase does • Adams, D. H., Bwchim. Biophys. Acta, ~. 1 (1949). hydrolyse benzoylcholine, at a rate which would • Fraser, P. ~-, ti:,esis, University of Birmingham (1951), and private commumcat10n (1956). account for such observations. In spite of this, • Aldridge, W. N., Biochem. J., 53, 62 (1953). Austin, L., and Berry some results obtained by Fraser with benzoylcholine• W. K., Bwchem. J., 54, 695 (1953). ' imply the existence of more than one type of cholin­ 'Bayliss, B.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2009/0156618 A1 Tollefson (43) Pub
    US 20090156618A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0156618 A1 Tollefson (43) Pub. Date: Jun. 18, 2009 (54) 1-(1-(2-ETHOXYETHYL)-3-ETHYL-7- Related U.S. Application Data (4-METHYLPYRIDIN-2-YLAMINO) - 1H-PYRAZOLO 4.3-D PYRIMIDIN-5-YL) (60) Provisional application No. 60/735,320, filed on Nov. PPERDINE-4-CARBOXYLIC ACID AND 10, 2005. SALTS THEREOF Publication Classification (51) Int. Cl. (75) Inventor: Michael B. Tollefson, Dardenne A 6LX 3/59 (2006.01) Prairie, MO (US) C07D 487/04 (2006.01) A6IP 9/12 (2006.01) A6IP 25/00 (2006.01) Correspondence Address: A6IP 9/00 (2006.01) PFZER INC. PATENT DEPARTMENT, Bld 114 M/S 114, (52) U.S. Cl. ...................................... 514/262.1; 54.4/262 EASTERN PONT ROAD (57) ABSTRACT GROTON, CT 06340 (US) The present invention comprises 1-(1-(2-ethoxyethyl)-3- ethyl-7-(4-methylpyridin-2-ylamino)-1H-pyrazolo 4.3-d (73) Assignee: Pfizer Inc pyrimidin-5-yl)piperidine-4-carboxylic acid and its salts. The invention further comprises pharmaceutical composi tions, methods of treatment, and synthetic methods relating to (21) Appl. No.: 111558,306 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2- ylamino)-1H-pyrazolo 4.3-dipyrimidin-5-yl)piperidine-4- (22) Filed: Nov. 9, 2006 carboxylic acid and its salts. Patent Application Publication Jun. 18, 2009 Sheet 2 of 2 US 2009/0156618 A1 "SOIHZ US 2009/0156618 A1 Jun. 18, 2009 1-(1-(2-ETHOXYETHYL)-3-ETHYL-7- 1H-pyrazolo 4,3-dipyrimidin-5-yl)piperidine-4-carboxylic (4-METHYLPYRIDIN-2-YLAMINO) - acid and its pharmaceutically acceptable salts.
    [Show full text]
  • The Anxiomimetic Properties of Pentylenetetrazol in the Rat
    University of Rhode Island DigitalCommons@URI Open Access Dissertations 1980 THE ANXIOMIMETIC PROPERTIES OF PENTYLENETETRAZOL IN THE RAT Gary Terence Shearman University of Rhode Island Follow this and additional works at: https://digitalcommons.uri.edu/oa_diss Recommended Citation Shearman, Gary Terence, "THE ANXIOMIMETIC PROPERTIES OF PENTYLENETETRAZOL IN THE RAT" (1980). Open Access Dissertations. Paper 165. https://digitalcommons.uri.edu/oa_diss/165 This Dissertation is brought to you for free and open access by DigitalCommons@URI. It has been accepted for inclusion in Open Access Dissertations by an authorized administrator of DigitalCommons@URI. For more information, please contact [email protected]. THE ANXIOMIMETIC PROPERTIES OF PENTYLENETETRAZOL IN THE RAT BY GARY TERENCE SHEARMAN A DISSERTATION SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY IN PHARMACEUTICAL SCIENCES (PHARMACOLOGY AND TOXICOLOGY) UNIVERSITY OF RHODE ISLAND 19 80 DOCTOR OF PHILOSOPHY DISSERT.A.TION OF GARY TERENCE SHEAffiil.AN Approved: Dissertation Cormnittee \\ Major Professor ~~-L_-_._dd__· _... _______ _ -~ar- Dean of the Graduate School UNIVERSITY OF RHODE ISLAND 1980 ABSTRACT Investigation of the biological basis of anxiety is ham­ pered by the lack of an appropriate animal model for research purposes. There are no known drugs that cause anxiety in laboratory animals. Pentylenetetrazol (PTZ) produces intense anxiety in human volunteers (Rodin, 1958; Rodin and Calhoun, 1970). Therefore, it was the major objective of this disser- tation to test the hypothesis that the discriminative stimu­ lus produced by PTZ in the rat was related to its anxiogenic action in man. It was also an objective to suggest the neuro- chemical basis for the discriminative stimulus property of PTZ through appropriate drug interactions.
    [Show full text]
  • Campro Catalog Stable Isotope
    Introduction & Welcome Dear Valued Customer, We are pleased to present to you our Stable Isotopes Catalog which contains more than three thousand (3000) high quality labeled compounds. You will find new additions that are beneficial for your research. Campro Scientific is proud to work together with Isotec, Inc. for the distribution and marketing of their stable isotopes. We have been working with Isotec for more than twenty years and know that their products meet the highest standard. Campro Scientific was founded in 1981 and we provide services to some of the most prestigious universities, research institutes and laboratories throughout Europe. We are a research-oriented company specialized in supporting the requirements of the scientific community. We are the exclusive distributor of some of the world’s leading producers of research chemicals, radioisotopes, stable isotopes and environmental standards. We understand the requirements of our customers, and work every day to fulfill them. In working with us you are guaranteed to receive: - Excellent customer service - High quality products - Dependable service - Efficient distribution The highly educated staff at Campro’s headquarters and sales office is ready to assist you with your questions and product requirements. Feel free to call us at any time. Sincerely, Dr. Ahmad Rajabi General Manager 180/280 = unlabeled 185/285 = 15N labeled 181/281 = double labeled (13C+15N, 13C+D, 15N+18O etc.) 186/286 = 12C labeled 182/282 = d labeled 187/287 = 17O labeled 183/283 = 13C labeleld 188/288 = 18O labeled 184/284 = 16O labeled, 14N labeled 189/289 = Noble Gases Table of Contents Ordering Information.................................................................................................. page 4 - 5 Packaging Information ..............................................................................................
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Sigma Fatty Acids, Glycerides, Oils and Waxes
    Sigma Fatty Acids, Glycerides, Oils and Waxes Library Listing – 766 spectra This library represents a material-specific subset of the larger Sigma Biochemical Condensed Phase Library relating to relating to fatty acids, glycerides, oils, and waxes found in the Sigma Biochemicals and Reagents catalog. Spectra acquired by Sigma-Aldrich Co. which were examined and processed at Thermo Fisher Scientific. The spectra include compound name, molecular formula, CAS (Chemical Abstract Service) registry number, and Sigma catalog number. Sigma Fatty Acids, Glycerides, Oils and Waxes Index Compound Name Index Compound Name 464 (E)-11-Tetradecenyl acetate 592 1-Monocapryloyl-rac-glycerol 118 (E)-2-Dodecenedioic acid 593 1-Monodecanoyl-rac-glycerol 99 (E)-5-Decenyl acetate 597 1-Monolauroyl-rac-glycerol 115 (E)-7,(Z)-9-Dodecadienyl acetate 599 1-Monolinolenoyl-rac-glycerol 116 (E)-8,(E)-10-Dodecadienyl acetate 600 1-Monolinoleoyl-rac-glycerol 4 (E)-Aconitic acid 601 1-Monomyristoyl-rac-glycerol 495 (E)-Vaccenic acid 598 1-Monooleoyl-rac-glycerol 497 (E)-Vaccenic acid methyl ester 602 1-Monopalmitoleoyl-rac-glycerol 98 (R)-(+)-2-Chloropropionic acid methyl 603 1-Monopalmitoyl-rac-glycerol ester 604 1-Monostearoyl-rac-glycerol; 1- 139 (Z)-11-Eicosenoic anhydride Glyceryl monosterate 180 (Z)-11-Hexadecenyl acetate 589 1-O-Hexadecyl-2,3-dipalmitoyl-rac- 463 (Z)-11-Tetradecenyl acetate glycerol 181 (Z)-3-Hexenyl acetate 588 1-O-Hexadecyl-rac-glycerol 350 (Z)-3-Nonenyl acetate 590 1-O-Hexadecyl-rac-glycerol 100 (Z)-5-Decenyl acetate 591 1-O-Hexadecyl-sn-glycerol
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • 2013 House Judiciary Hb 1070
    2013 HOUSE JUDICIARY HB 1070 2013 HOUSE STANDING COMMITTEE MINUTES House Judiciary Committee Prairie Room, State Capitol HB 1070 January 14, 2013 Job #17167 D Conference Committee � · Committee Clerk Signature A-. .;' /) .1� ' I A.J4-��'N'f?4<'71<P2/ I Explanation or reason for introduction of bill/resolution: Relating to the scheduling of controlled substances. Minutes: Chairman Koppelman: Opened the hearing on HB 1070. Mark Hardy, Assistant Executive Director of the NO State Board of Pharmacy: (See testimony #1and 2) He went over these handouts. Rep. Klemin: I don't see an emergency clause in the bill and there is none in the amendment. Did I miss it? Mark Hardy: I want to put an emergency clause on the bill. Rep. Klemin: I think you have to have another section at the end of the bill saying this is an emergency. Rep. Kretschmar: How often do these new drugs come out and should be on it? Mark Hardy: As far as the schedule 1 substances; it is a revolving door and we are always trying to stay in front of what the chemists and what the drug makers are doing. As far as schedule 2 through 5; it is a continuous thing through the DEA. When it becomes a federally controlled substance it takes precedence. Rep. Larson: You have not been aware of the bill I was sponsoring regarding synthetic drugs yet? Mark Hardy: No. The Attorney General briefed me on the Bill #1133. Rep. Larson: The reason for my bill is not get into all of the pharmaceutical names of the chemicals, but anybody that possess or manufacturers a analog in order to try and copy these drugs would be guilty of those offences without having to know the specific chemical compound that might be morphed by unscrupulous people trying to see these products.
    [Show full text]
  • Aldrich Raman
    Aldrich Raman Library Listing – 14,033 spectra This library represents the most comprehensive collection of FT-Raman spectral references available. It contains many common chemicals found in the Aldrich Handbook of Fine Chemicals. To create the Aldrich Raman Condensed Phase Library, 14,033 compounds found in the Aldrich Collection of FT-IR Spectra Edition II Library were excited with an Nd:YVO4 laser (1064 nm) using laser powers between 400 - 600 mW, measured at the sample. A Thermo FT-Raman spectrometer (with a Ge detector) was used to collect the Raman spectra. The spectra were saved in Raman Shift format. Aldrich Raman Index Compound Name Index Compound Name 4803 ((1R)-(ENDO,ANTI))-(+)-3- 4246 (+)-3-ISOPROPYL-7A- BROMOCAMPHOR-8- SULFONIC METHYLTETRAHYDRO- ACID, AMMONIUM SALT PYRROLO(2,1-B)OXAZOL-5(6H)- 2207 ((1R)-ENDO)-(+)-3- ONE, BROMOCAMPHOR, 98% 12568 (+)-4-CHOLESTEN-3-ONE, 98% 4804 ((1S)-(ENDO,ANTI))-(-)-3- 3774 (+)-5,6-O-CYCLOHEXYLIDENE-L- BROMOCAMPHOR-8- SULFONIC ASCORBIC ACID, 98% ACID, AMMONIUM SALT 11632 (+)-5-BROMO-2'-DEOXYURIDINE, 2208 ((1S)-ENDO)-(-)-3- 97% BROMOCAMPHOR, 98% 11634 (+)-5-FLUORODEOXYURIDINE, 769 ((1S)-ENDO)-(-)-BORNEOL, 99% 98+% 13454 ((2S,3S)-(+)- 11633 (+)-5-IODO-2'-DEOXYURIDINE, 98% BIS(DIPHENYLPHOSPHINO)- 4228 (+)-6-AMINOPENICILLANIC ACID, BUTANE)(N3-ALLYL)PD(II) CL04, 96% 97 8167 (+)-6-METHOXY-ALPHA-METHYL- 10297 ((3- 2- NAPHTHALENEACETIC ACID, DIMETHYLAMINO)PROPYL)TRIPH 98% ENYL- PHOSPHONIUM BROMIDE, 12586 (+)-ANDROSTA-1,4-DIENE-3,17- 99% DIONE, 98% 13458 ((R)-(+)-2,2'- 963 (+)-ARABINOGALACTAN BIS(DIPHENYLPHOSPHINO)-1,1'-
    [Show full text]
  • 4 Supplementary File
    Supplemental Material for High-throughput screening discovers anti-fibrotic properties of Haloperidol by hindering myofibroblast activation Michael Rehman1, Simone Vodret1, Luca Braga2, Corrado Guarnaccia3, Fulvio Celsi4, Giulia Rossetti5, Valentina Martinelli2, Tiziana Battini1, Carlin Long2, Kristina Vukusic1, Tea Kocijan1, Chiara Collesi2,6, Nadja Ring1, Natasa Skoko3, Mauro Giacca2,6, Giannino Del Sal7,8, Marco Confalonieri6, Marcello Raspa9, Alessandro Marcello10, Michael P. Myers11, Sergio Crovella3, Paolo Carloni5, Serena Zacchigna1,6 1Cardiovascular Biology, 2Molecular Medicine, 3Biotechnology Development, 10Molecular Virology, and 11Protein Networks Laboratories, International Centre for Genetic Engineering and Biotechnology (ICGEB), Padriciano, 34149, Trieste, Italy 4Institute for Maternal and Child Health, IRCCS "Burlo Garofolo", Trieste, Italy 5Computational Biomedicine Section, Institute of Advanced Simulation IAS-5 and Institute of Neuroscience and Medicine INM-9, Forschungszentrum Jülich GmbH, 52425, Jülich, Germany 6Department of Medical, Surgical and Health Sciences, University of Trieste, 34149 Trieste, Italy 7National Laboratory CIB, Area Science Park Padriciano, Trieste, 34149, Italy 8Department of Life Sciences, University of Trieste, Trieste, 34127, Italy 9Consiglio Nazionale delle Ricerche (IBCN), CNR-Campus International Development (EMMA- INFRAFRONTIER-IMPC), Rome, Italy This PDF file includes: Supplementary Methods Supplementary References Supplementary Figures with legends 1 – 18 Supplementary Tables with legends 1 – 5 Supplementary Movie legends 1, 2 Supplementary Methods Cell culture Primary murine fibroblasts were isolated from skin, lung, kidney and hearts of adult CD1, C57BL/6 or aSMA-RFP/COLL-EGFP mice (1) by mechanical and enzymatic tissue digestion. Briefly, tissue was chopped in small chunks that were digested using a mixture of enzymes (Miltenyi Biotec, 130- 098-305) for 1 hour at 37°C with mechanical dissociation followed by filtration through a 70 µm cell strainer and centrifugation.
    [Show full text]
  • 1 Abietic Acid R Abrasive Silica for Polishing DR Acenaphthene M (LC
    1 abietic acid R abrasive silica for polishing DR acenaphthene M (LC) acenaphthene quinone R acenaphthylene R acetal (see 1,1-diethoxyethane) acetaldehyde M (FC) acetaldehyde-d (CH3CDO) R acetaldehyde dimethyl acetal CH acetaldoxime R acetamide M (LC) acetamidinium chloride R acetamidoacrylic acid 2- NB acetamidobenzaldehyde p- R acetamidobenzenesulfonyl chloride 4- R acetamidodeoxythioglucopyranose triacetate 2- -2- -1- -β-D- 3,4,6- AB acetamidomethylthiazole 2- -4- PB acetanilide M (LC) acetazolamide R acetdimethylamide see dimethylacetamide, N,N- acethydrazide R acetic acid M (solv) acetic anhydride M (FC) acetmethylamide see methylacetamide, N- acetoacetamide R acetoacetanilide R acetoacetic acid, lithium salt R acetobromoglucose -α-D- NB acetohydroxamic acid R acetoin R acetol (hydroxyacetone) R acetonaphthalide (α)R acetone M (solv) acetone ,A.R. M (solv) acetone-d6 RM acetone cyanohydrin R acetonedicarboxylic acid ,dimethyl ester R acetonedicarboxylic acid -1,3- R acetone dimethyl acetal see dimethoxypropane 2,2- acetonitrile M (solv) acetonitrile-d3 RM acetonylacetone see hexanedione 2,5- acetonylbenzylhydroxycoumarin (3-(α- -4- R acetophenone M (LC) acetophenone oxime R acetophenone trimethylsilyl enol ether see phenyltrimethylsilyl... acetoxyacetone (oxopropyl acetate 2-) R acetoxybenzoic acid 4- DS acetoxynaphthoic acid 6- -2- R 2 acetylacetaldehyde dimethylacetal R acetylacetone (pentanedione -2,4-) M (C) acetylbenzonitrile p- R acetylbiphenyl 4- see phenylacetophenone, p- acetyl bromide M (FC) acetylbromothiophene 2- -5-
    [Show full text]
  • Chemical Trends in Solid Alkali Pertechnetates † ‡ ‡ ‡ ‡ ‡ Jamie Weaver, , Chuck Z
    This is an open access article published under an ACS AuthorChoice License, which permits copying and redistribution of the article or any adaptations for non-commercial purposes. Article pubs.acs.org/IC Chemical Trends in Solid Alkali Pertechnetates † ‡ ‡ ‡ ‡ ‡ Jamie Weaver, , Chuck Z. Soderquist, Nancy M. Washton, Andrew S. Lipton, Paul L. Gassman, § ∥ † † ‡ ⊥ Wayne W. Lukens, Albert A. Kruger, Nathalie A. Wall, and John S. McCloy*, , , † Department of Chemistry, Washington State University, Pullman, Washington 99164, United States ‡ Pacific Northwest National Laboratory, Richland, Washington 99352, United States § Lawrence Berkeley National Laboratory, Berkeley, California 94720, United States ∥ U.S. Department of Energy (DOE), Office of River Protection, Richland, Washington 99352, United States ⊥ Materials Science and Engineering Program and School of Mechanical & Materials Engineering, Washington State University, Pullman, Washington 99164, United States *S Supporting Information ABSTRACT: Insight into the solid-state chemistry of pure technetium-99 (99Tc) oxides is required in the development of a robust immobilization and disposal system for nuclear waste stemming from the radiopharmaceutical industry, from the production of nuclear weapons, and from spent nuclear fuel. However, because of its radiotoxicity and the subsequent requirement of special facilities and handling procedures for research, only a few studies have been completed, many of which are over 20 years old. In this study, we report the synthesis of pure alkali pertechnetates (sodium, potassium, rubidium, and cesium) and analysis of these compounds by Raman spectroscopy, X-ray absorption spectroscopy (XANES and EXAFS), solid-state nuclear magnetic resonance (static and magic angle spinning), and neutron diffraction. The structures and spectral signatures of these compounds will aid in refining the understanding of 99Tc incorporation into and release from nuclear waste glasses.
    [Show full text]